VISEN Pharmaceuticals (HKG:2561) said Chinese regulators approved the company's biologics license application for lonapegsomatropin, according to a Hong Kong bourse filing Monday.
The medicine, which holds the Skytrofa trade name, is meant to be used as a once-weekly growth hormone replacement therapy in patients three years and older.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.